Scientific article

Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab"

Published inJournal der Deutschen Dermatologischen Gesellschaft, vol. 8, no. 1, p. 65-66
Publication date2010

In February 2009, the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) had recommended the suspension of efalizumab's (Raptiva) marketing authorization, because its benefits in the treatment of psoriasis were modest, while there was a risk of serious side effects in patients receiving the medicine, including the occurrence of progressive multifocal leukoencephalopathy (PML). The guideline group has changed the guideline accordingly.

  • Antibodies, Monoclonal/adverse effects/*therapeutic use
  • Dermatology/*standards
  • European Union
  • *Evidence-Based Medicine
  • Humans
  • *Practice Guidelines as Topic
  • Psoriasis/*drug therapy
Affiliation Not a UNIGE publication
Citation (ISO format)
NAST, Alexander et al. Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: ‘Therapeutic options’ and ‘Efalizumab’. In: Journal der Deutschen Dermatologischen Gesellschaft, 2010, vol. 8, n° 1, p. 65–66. doi: 10.1111/j.1610-0387.2009.07312_supp.x
Main files (1)
ISSN of the journal1610-0379

Technical informations

Creation09/20/2013 4:48:59 PM
First validation09/20/2013 4:48:59 PM
Update time03/14/2023 8:26:15 PM
Status update03/14/2023 8:26:14 PM
Last indexation02/12/2024 8:34:10 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack